The National Institute of Health (NIH) is determined to reduce the cost and time it takes to discover viable therapeutic targets, which drive the changes in the molecular networks leading to the signs and symptoms of Alzheimer’s disease.
NIH is leading the U.S. Food and Drug Administration and various other industry and academic scientists in a public-private partnership effort to create a Big Data portal for Alzheimer’s drug discovery. This Accelerating Medicine Partnership for Alzheimer’s disease (AMP-AD) Knowledge Portal is public so it will enable sharing, transparency, reproducibility, and analysis of large biomedical datasets. The hope is that it will shorten the time between discovery of potential drug targets to development of new drugs for the treatment and prevention of Alzheimer’s disease.
The AMP-AD Knowledge Portal is available on Synapse, which is a public workspace that allows registered users to aggregate, describe, and share their research. AMP-AD data is available for users to incorporate into their own research programs and may be analyzed in combination with other data.